A top proxy adviser and the ex-CEO of a Fortune 500 pharmaceutical company once targeted by an billionaire activist on Wednesday clashed over the role two advisory firms play in boardroom battles pitting insurgent-backed dissident directors against incumbent executives. "We should all be playing by the same rules," Robert Coury, Mylan Inc.'s executive chairman, told the U.S. Chamber of Commerce ...